Does @elilillyandcompany.bsky.social have a winner in #EloraTZP for obesity in diabetes? Data from #EASD2026 suggests it might.
conscienhealth.org/2026/10/01/e...
conscienhealth.org/2026/10/01/e...
October 1, 2026 at 10:10 AM
Does @elilillyandcompany.bsky.social have a winner in #EloraTZP for obesity in diabetes? Data from #EASD2026 suggests it might.
conscienhealth.org/2026/10/01/e...
conscienhealth.org/2026/10/01/e...
New Phase 3 data on retatrutide shows adults with obesity & T2D lost up to 49.6 lbs (20.8%) & lowered A1C by 1.6% at 80 weeks. How will potent new medications like this redefine how we manage cardiometabolic health conditions long-term?
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to chan
Eli Lilly and Company announced new data from its cardiometabolic health portfolio, including pivotal Phase 3 results for retatrutide, an investigational triple hormone receptor agonist. This medicati
www.fidelity.com
September 16, 2026 at 2:03 AM
New Phase 3 data on retatrutide shows adults with obesity & T2D lost up to 49.6 lbs (20.8%) & lowered A1C by 1.6% at 80 weeks. How will potent new medications like this redefine how we manage cardiometabolic health conditions long-term?
Lilly's EloraTZP showed an average 23.3% bodyweight reduction in 48 weeks in Phase IIb results in people with T2D and obesity.Tirzepatide alone: 14.8%. Placebo: 3%. One number complicates it:discontinuations due to adverse events ranged from 10.8% to 27%.Trial Tuesday www.capsul.news/trial-tuesda...
October 6, 2026 at 10:24 AM
Lilly's EloraTZP showed an average 23.3% bodyweight reduction in 48 weeks in Phase IIb results in people with T2D and obesity.Tirzepatide alone: 14.8%. Placebo: 3%. One number complicates it:discontinuations due to adverse events ranged from 10.8% to 27%.Trial Tuesday www.capsul.news/trial-tuesda...
Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster: EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
dlvr.it
September 30, 2026 at 4:44 PM
Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster: EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
Eli Lilly’s experimental combination of eloralintide and tirzepatide, nicknamed EloraTZP, helped adults with type 2 diabetes and obesity lose an average of 23.3% of their body weight over 48 weeks, according to a phase 2 trial covered in the reporting behind…
Eli Lilly’s [Drug Combo Shows Record Weight Loss for Diabetes Patients](https://blavity.com/eli-lilly-drug-combo-record-weight-loss-diabetes) in New Trial
Eli Lilly’s experimental combination of eloralintide and tirzepatide, nicknamed EloraTZP, helped adults with type 2 diabetes and obesity lose an average of 23.3% of their body weight over 48 weeks, according to a phase 2 trial covered in the reporting behind https://blavity.com/eli-lilly-drug-combo-record-weight-loss-diabetes. That is roughly 54 pounds for an average participant, a result researchers call […]
uticaphoenix.net
October 6, 2026 at 12:49 PM
Eli Lilly’s experimental combination of eloralintide and tirzepatide, nicknamed EloraTZP, helped adults with type 2 diabetes and obesity lose an average of 23.3% of their body weight over 48 weeks, according to a phase 2 trial covered in the reporting behind…
⚡ Breaking: Lilly's amylin-Zepbound combo breaks a weight loss record
Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination delive...
endpoints.news
September 30, 2026 at 2:31 PM
⚡ Breaking: Lilly's amylin-Zepbound combo breaks a weight loss record
💉 #pharma #EASD2026
Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 #$LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 #$NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%.
Separate trials, 68-80 wk. No EloraTZP: on-drug data only.
midgardfinance.com/diabetes/
Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 #$LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 #$NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%.
Separate trials, 68-80 wk. No EloraTZP: on-drug data only.
midgardfinance.com/diabetes/
October 1, 2026 at 8:46 AM
💉 #pharma #EASD2026
Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 #$LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 #$NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%.
Separate trials, 68-80 wk. No EloraTZP: on-drug data only.
midgardfinance.com/diabetes/
Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 #$LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 #$NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%.
Separate trials, 68-80 wk. No EloraTZP: on-drug data only.
midgardfinance.com/diabetes/
Eli Lilly's EloraTZP Proves Effective in Weight Loss and A1C Reduction in Obesity and Diabetes Patients#United_States#Indianapolis#tirzepatide#Eli_Lilly#EloraTZP
Eli Lilly's EloraTZP Proves Effective in Weight Loss and A1C Reduction in Obesity and Diabetes Patients
Eli Lilly announces successful Phase 2b results for EloraTZP, showcasing improved weight loss and A1C reduction for adults with obesity and type 2 diabetes.
third-news.com
September 30, 2026 at 2:35 PM
Eli Lilly's EloraTZP Proves Effective in Weight Loss and A1C Reduction in Obesity and Diabetes Patients#United_States#Indianapolis#tirzepatide#Eli_Lilly#EloraTZP
ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE
September 30, 2026 at 2:16 PM
ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE
ICYMI: Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster: EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
dlvr.it
October 1, 2026 at 4:46 PM
ICYMI: Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster: EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
UPDATE: Eli Lilly's EloraTZP combination therapy showed up to 23.3% weight loss in mid-stage trials, with Phase 3 development planned for later this year. | BioSpace
September 30, 2026 at 2:22 PM
UPDATE: Eli Lilly's EloraTZP combination therapy showed up to 23.3% weight loss in mid-stage trials, with Phase 3 development planned for later this year. | BioSpace
In Lilly’s 367-person Phase 2b diabetes trial, EloraTZP produced up to 23.3% mean weight loss versus 14.8% with tirzepatide at 48 weeks. Adverse-event discontinuations were higher in combination arms; Phase 3 remains ahead.
September 30, 2026 at 2:52 PM
In Lilly’s 367-person Phase 2b diabetes trial, EloraTZP produced up to 23.3% mean weight loss versus 14.8% with tirzepatide at 48 weeks. Adverse-event discontinuations were higher in combination arms; Phase 3 remains ahead.
Good News of the Day: A new investigational drug combo, EloraTZP, helped people with obesity and type 2 diabetes lose up to 23.3% of their weight in 48 weeks, with major improvements in blood sugar control.
#GoodNews #PositiveNews #HealthNews #Wellness #MedicalBreakthrough
#GoodNews #PositiveNews #HealthNews #Wellness #MedicalBreakthrough
New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
A new drug combo called EloraTZP helped people with obesity and type 2 diabetes lose up to 23.3% of their body weight in a 48-week trial. It also greatly improved blood sugar control, offering new hope for effective treatment.
www.meridia.news
October 1, 2026 at 5:00 AM
Good News of the Day: A new investigational drug combo, EloraTZP, helped people with obesity and type 2 diabetes lose up to 23.3% of their weight in 48 weeks, with major improvements in blood sugar control.
#GoodNews #PositiveNews #HealthNews #Wellness #MedicalBreakthrough
#GoodNews #PositiveNews #HealthNews #Wellness #MedicalBreakthrough
ICYMI: Lilly's new drug combo beats Ozempic's rival — by a wide margin #WeightLoss #ObesityTreatment
Lilly's new drug combo beats Ozempic's rival — by a wide margin
Eli Lilly's experimental EloraTZP helped patients lose 23% of their body weight — nearly 10 points more than tirzepatide alone — signaling a potential new ceiling for obesity treatment. The catch: far more patients dropped out due to side effects, a hurdle Lilly says it can engineer away before Phase 3 trials begin.
dlvr.it
October 1, 2026 at 11:36 PM
ICYMI: Lilly's new drug combo beats Ozempic's rival — by a wide margin #WeightLoss #ObesityTreatment
Lilly's combo moved the goalposts 🎯💊
#$LLY EloraTZP (amylin + Zepbound) hit 23.3% weight loss in Phase 2 diabetes patients vs 14.8% on Zepbound alone — A1C down 2.9%.
Citi's bar was 18%. Cleared it.
Watch: 10.8–27% dropout rate.
$1.08T cap, stock +0.45% — muted.
[NOT FINANCIAL ADVICE, DYOR!]
#$LLY EloraTZP (amylin + Zepbound) hit 23.3% weight loss in Phase 2 diabetes patients vs 14.8% on Zepbound alone — A1C down 2.9%.
Citi's bar was 18%. Cleared it.
Watch: 10.8–27% dropout rate.
$1.08T cap, stock +0.45% — muted.
[NOT FINANCIAL ADVICE, DYOR!]
September 30, 2026 at 2:25 PM
Lilly's combo moved the goalposts 🎯💊
#$LLY EloraTZP (amylin + Zepbound) hit 23.3% weight loss in Phase 2 diabetes patients vs 14.8% on Zepbound alone — A1C down 2.9%.
Citi's bar was 18%. Cleared it.
Watch: 10.8–27% dropout rate.
$1.08T cap, stock +0.45% — muted.
[NOT FINANCIAL ADVICE, DYOR!]
#$LLY EloraTZP (amylin + Zepbound) hit 23.3% weight loss in Phase 2 diabetes patients vs 14.8% on Zepbound alone — A1C down 2.9%.
Citi's bar was 18%. Cleared it.
Watch: 10.8–27% dropout rate.
$1.08T cap, stock +0.45% — muted.
[NOT FINANCIAL ADVICE, DYOR!]
#EliLilly's bid to dominate the next generation of #weightlosstherapies has been strengthened by data on a new #combinationtherapy that combines its GIP/GLP-1 agonist tirzepatide with amylin-targeting eloralintide.
pharmaphorum.com/news/new-lil...
pharmaphorum.com/news/new-lil...
New Lilly combo tops tirzepatide for weight loss in diabetes
Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.
pharmaphorum.com
October 1, 2026 at 9:39 AM
#EliLilly's bid to dominate the next generation of #weightlosstherapies has been strengthened by data on a new #combinationtherapy that combines its GIP/GLP-1 agonist tirzepatide with amylin-targeting eloralintide.
pharmaphorum.com/news/new-lil...
pharmaphorum.com/news/new-lil...
Lilly's new drug combo beats Ozempic's rival — by a wide margin #EliLilly #WeightLoss
Lilly's new drug combo beats Ozempic's rival — by a wide margin
Eli Lilly's experimental EloraTZP helped patients lose 23% of their body weight — nearly 10 points more than tirzepatide alone — signaling a potential new ceiling for obesity treatment. The catch: far more patients dropped out due to side effects, a hurdle Lilly says it can engineer away before Phase 3 trials begin.
dlvr.it
September 30, 2026 at 11:35 PM
Lilly's new drug combo beats Ozempic's rival — by a wide margin #EliLilly #WeightLoss
Eli Lilly Unveils Revolutionary Cardiometabolic Health Data at EASD 2026#USA#Indianapolis#Eli_Lilly#retatrutide#Foundayo
Eli Lilly Unveils Revolutionary Cardiometabolic Health Data at EASD 2026
Eli Lilly is set to present groundbreaking findings on Foundayo, retatrutide, and eloraTZP at the 2026 EASD conference, reshaping cardiometabolic health strategies.
third-news.com
September 15, 2026 at 10:54 AM
Eli Lilly Unveils Revolutionary Cardiometabolic Health Data at EASD 2026#USA#Indianapolis#Eli_Lilly#retatrutide#Foundayo